The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor

Study Overview
=================
Brief Summary
-----------------
As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies. In recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising. The key to gynecologic malignancies is how to early diagnose and treat. With the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. Genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. Therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.

Official Title
-----------------
The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor

Conditions
-----------------
Gynecologic Malignant Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female aging from 16 to 75-year old; Preoperative diagnosis of gynecologic malignancies; Have the ability to comply with Research programs; Voluntarily participate in the study and signed an informed consent form Exclusion Criteria: The cases do not meet the inclusion criteria should be removed from,indicating the reason for excluding.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experiment group<br>patients with cervical cancer, endometrial cancers or ovary cancer | |
| control group<br>postmenopausal women with benign tumor | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene mutation from species of cervical cancer, endometrial cancers and ovary cancer | We expect to found spcific DNA mutation in the species (peripheral blood, liquid Pap smear and cancer tissue) from cervical cancer, endometrial cancers and ovary. | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the difference between detection sensitivity | Comparing sensiitivity of the three kinds of samples on early detection of gynecologic malignancies | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cervical cancer, ovarian cancer, endometrial cancer, high-throughput sequencing